Log in

NASDAQ:TLRYTilray Stock Price, Forecast & News

$10.26
+0.61 (+6.32 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.90
Now: $10.26
$10.69
50-Day Range
$5.54
MA: $7.20
$9.65
52-Week Range
$2.43
Now: $10.26
$51.03
Volume43.10 million shs
Average Volume13.42 million shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.29
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Read More
Tilray logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone206-432-9325

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$166.98 million
Book Value$2.78 per share

Profitability

Net Income$-321,170,000.00
Net Margins-241.79%

Miscellaneous

Employees1,646
Market Cap$1.28 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.

Tilray (NASDAQ:TLRY) Frequently Asked Questions

How has Tilray's stock been impacted by COVID-19 (Coronavirus)?

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TLRY stock has increased by 44.7% and is now trading at $10.26. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tilray?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tilray.

When is Tilray's next earnings date?

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Tilray.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) released its quarterly earnings results on Monday, May, 11th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($0.44) by $1.29. The firm had revenue of $52.20 million for the quarter, compared to the consensus estimate of $49.37 million. Tilray had a negative return on equity of 62.82% and a negative net margin of 241.79%. Tilray's revenue was up 127.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.27) EPS. View Tilray's earnings history.

What price target have analysts set for TLRY?

17 brokerages have issued 1 year price objectives for Tilray's stock. Their forecasts range from $4.00 to $54.00. On average, they anticipate Tilray's stock price to reach $17.88 in the next year. This suggests a possible upside of 74.3% from the stock's current price. View analysts' price targets for Tilray.

Has Tilray been receiving favorable news coverage?

Media coverage about TLRY stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tilray earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutTilray.

Are investors shorting Tilray?

Tilray saw a increase in short interest in April. As of April 15th, there was short interest totaling 16,520,000 shares, an increase of 7.8% from the March 31st total of 15,330,000 shares. Based on an average daily trading volume, of 9,370,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 21.2% of the shares of the stock are short sold. View Tilray's Current Options Chain.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and Square (SQ).

Who are Tilray's key executives?

Tilray's management team includes the following people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of institutional and retail investors. Top institutional investors include ETF Managers Group LLC (2.47%), CIBC World Markets Inc. (0.16%), Advisor Group Holdings Inc. (0.08%), Geode Capital Management LLC (0.05%), Stelac Advisory Services LLC (0.06%) and Thrivent Financial for Lutherans (0.04%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View institutional ownership trends for Tilray.

Which major investors are selling Tilray stock?

TLRY stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Commerzbank Aktiengesellschaft FI, AdvisorShares Investments LLC, BNP Paribas Arbitrage SA, Stelac Advisory Services LLC, and Exane Derivatives. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, and Michael Auerbach. View insider buying and selling activity for Tilray.

Which major investors are buying Tilray stock?

TLRY stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, CIBC World Markets Inc., Advisor Group Holdings Inc., Thrivent Financial for Lutherans, UBS Group AG, Cambridge Investment Research Advisors Inc., Two Sigma Advisers LP, and Commonwealth Equity Services LLC. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy, and Edward Wood Pastorius Jr. View insider buying and selling activity for Tilray.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $10.26.

How big of a company is Tilray?

Tilray has a market capitalization of $1.28 billion and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

What is Tilray's official website?

The official website for Tilray is www.tilray.com.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.